# Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

> **NCT02881853** · PHASE1 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Healthy Volunteers
- Atopic Disease

## Interventions

- **DRUG:** XmAb7195
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02881853
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-17
- **Primary completion:** 2017-02-24
- **Final completion:** 2017-02-24
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02881853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02881853, "Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02881853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*